|
🐜
|
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis
14 auth.
K. Machiels,
M. Joossens,
J. Sabino,
V. De Preter,
I. Arijs,
V. Eeckhaut,
V. Ballet,
K. Claes,
F. Van Immerseel,
K. Verbeke,
...
M. Ferrante,
J. Verhaegen,
P. Rutgeerts,
S. Vermeire
|
10 |
2013 |
10
🐜
|
|
🐜
|
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
10 auth.
N. Vande Casteele,
M. Ferrante,
G. Van Assche,
V. Ballet,
G. Compernolle,
K. van Steen,
...
S. Simoens,
P. Rutgeerts,
A. Gils,
S. Vermeire
|
9 |
2015 |
9
🐜
|
|
🐜
|
Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD
11 auth.
J. Sabino,
S. Vieira-Silva,
K. Machiels,
M. Joossens,
G. Falony,
V. Ballet,
...
M. Ferrante,
G. Van Assche,
S. van der Merwe,
S. Vermeire,
J. Raes
|
8 |
2016 |
8
🐜
|
|
🐜
|
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy
11 auth.
F. Schnitzler,
H. Fidder,
M. Ferrante,
V. Ballet,
M. Noman,
G. Van Assche,
...
B. Spitz,
I. Hoffman,
K. van Steen,
S. Vermeire,
P. Rutgeerts
|
7 |
2011 |
7
🐜
|
|
🐜
|
Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.
13 auth.
M. Jürgens,
J. M. Mahachie John,
I. Cleynen,
F. Schnitzler,
H. Fidder,
W. van Moerkercke,
V. Ballet,
M. Noman,
I. Hoffman,
G. Van Assche,
...
P. Rutgeerts,
K. van Steen,
S. Vermeire
|
7 |
2011 |
7
🐜
|
|
🐬
|
Efficacy and safety of anti‐TNF therapy in elderly patients with inflammatory bowel disease
T. Lobatón,
M. Ferrante,
P. Rutgeerts,
V. Ballet,
G. Assche,
S. Vermeire
|
7 |
2015 |
7
🐬
|
|
🐜
|
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
11 auth.
G. Van Assche,
S. Vermeire,
V. Ballet,
F. Gabriels,
M. Noman,
G. D'Haens,
...
C. Claessens,
E. Humblet,
N. Vande Casteele,
A. Gils,
P. Rutgeerts
|
7 |
2011 |
7
🐜
|
|
🐜
|
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
16 auth.
D. Drobne,
P. Bossuyt,
C. Breynaert,
T. Cattaert,
N. Vande Casteele,
G. Compernolle,
M. Jürgens,
M. Ferrante,
V. Ballet,
W. Wollants,
...
I. Cleynen,
K. van Steen,
A. Gils,
P. Rutgeerts,
S. Vermeire,
G. Van Assche
|
7 |
2015 |
7
🐜
|
|
🐜
|
Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial
13 auth.
R. Bisschops,
T. Bessissow,
J. Joseph,
F. Baert,
M. Ferrante,
V. Ballet,
H. Willekens,
I. Demedts,
K. Geboes,
G. De Hertogh,
...
S. Vermeire,
P. Rutgeerts,
G. Van Assche
|
6 |
2017 |
6
🐜
|
|
🐜
|
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
10 auth.
B. Verstockt,
S. Verstockt,
J. Dehairs,
V. Ballet,
H. Blevi,
W. Wollants,
...
C. Breynaert,
G. Van Assche,
S. Vermeire,
M. Ferrante
|
6 |
2019 |
6
🐜
|
|
🐬
|
Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial
M. Joossens,
V. De Preter,
V. Ballet,
K. Verbeke,
P. Rutgeerts,
S. Vermeire
|
6 |
2011 |
6
🐬
|
